A Randomized, Double-Blind, Placebo Controlled, Multicenter, 12-week Phase 3 Study to Evaluate Efficacy and Safety of ALS-L1023 Tablet in Patients With Abdominal Obesity of Metabolic Syndrome
Phase of Trial: Phase III
Latest Information Update: 13 Oct 2016
At a glance
- Drugs ALS L1023 (Primary)
- Indications Obesity
- Focus Registrational; Therapeutic Use
- Sponsors Hanmi Pharmaceutical
- 10 Oct 2016 Status changed from recruiting to discontinued.
- 11 Jun 2013 New source identiofied and integrated: ClinicalTrials.gov record.
- 11 Jun 2013 Status changed from planning to recruiting as reported by the ClinicalTrials.gov record.